AA
IRON icon

ALPS Advisors’s Disc Medicine IRON Stock Holding History

ALPS Advisors’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Buy
31,058
+56
+0.2% +$3.89K 0.01% 404
2025
Q4 		$2.46M Buy
31,002
+14,210
+85% +$1.2M 0.01% 361
2025
Q3 		$1.11M Sell
16,792
-1,834
-10% -$109K 0.01% 494
2025
Q2 		$986K Sell
18,626
-6,853
-27% -$322K 0.01% 504
2025
Q1 		$1.26M Buy
25,479
+1,412
+6% +$78.5K 0.01% 422
2024
Q4 		$1.53M Buy
24,067
+1,179
+5% +$68.2K 0.01% 387
2024
Q3 		$1.12M Buy
22,888
+3,586
+19% +$168K 0.01% 468
2024
Q2 		$870K Buy
19,302
+2,272
+13% +$77.2K 0.01% 497
2024
Q1 		$1.06M Buy
17,030
+880
+5% +$57.1K 0.01% 464
2023
Q4 		$933K Sell
16,150
-750
-4% -$38.4K 0.01% 498
2023
Q3 		$794K Buy
16,900
+2,346
+16% +$117K 0.01% 521
2023
Q2 		$646K Buy
+14,554
New +$516K 0.01% 566
2021
Q4 		– Sell
-1,761
Closed -$213K – 929
2021
Q3 		$213K Sell
1,761
-129
-7% -$17.6K ﹤0.01% 896
2021
Q2 		$367K Buy
+1,890
New +$621K ﹤0.01% 637

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

ALPS Advisors's IRON Position: Q1 2026 in Review

ALPS Advisors increased its Disc Medicine (IRON) stake by 0.18% in Q1 2026, buying an estimated $3.89K and bringing the position to 31,058 shares worth $1.99M. The position accounts for 0.01% of the portfolio, ranked #404.

ALPS Advisors first reported a position in IRON in Q2 2021 and has held it in 14 quarters since. The position peaked at $2.46M in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • ALPS Advisors held 31,058 shares of Disc Medicine worth $1.99M as of Q1 2026.
  • ALPS Advisors bought 56 Disc Medicine shares in Q1 2026, an estimated $3.89K.
  • Disc Medicine made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #404 holding.
  • ALPS Advisors first reported a position in Disc Medicine in Q2 2021 and has held it in 14 quarters since.
  • ALPS Advisors's Disc Medicine position peaked at $2.46M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.